Investment Rating - The investment rating for the company is "Accumulate" (maintained) with a current price of 61.50 yuan [6]. Core Views - The company reported a revenue of 114 million yuan for the first three quarters of 2025, representing a year-on-year growth of 5.17%. However, the net profit attributable to shareholders decreased by 4.22% to 30 million yuan, and the net profit after deducting non-recurring gains and losses fell by 6.09% to 27 million yuan [6][11]. - The third quarter of 2025 saw a revenue of 38 million yuan, a year-on-year increase of 4.55%, but the net profit attributable to shareholders declined by 4.64% to 11 million yuan, indicating that the company's performance was below expectations due to macroeconomic pressures [6][7][9]. Summary by Sections Revenue Performance - The revenue growth rate was lower than expected, influenced by increased macroeconomic pressures. The company achieved a revenue of 38 million yuan in Q3 2025, which is similar to the 39 million yuan in Q2 2025, indicating a trend of single-digit growth [7][9]. Profitability - The company's overall performance was below expectations, with a gross margin of 68.70% in Q3 2025, down 1.30 percentage points from Q3 2024. The net margin also decreased to 27.50%, down 3.02 percentage points year-on-year, attributed to product price reductions [9][11]. Financial Forecast - The company is expected to achieve revenues of 175 million yuan, 203 million yuan, and 223 million yuan for the years 2025, 2026, and 2027, respectively, with year-on-year growth rates of 18.81%, 15.70%, and 10.08%. The net profit attributable to shareholders is projected to be 58 million yuan, 66 million yuan, and 73 million yuan for the same years, with growth rates of 40.00%, 13.36%, and 10.24% [10][11]. Valuation Metrics - The earnings per share (EPS) are forecasted to be 1.50 yuan, 1.70 yuan, and 1.88 yuan for 2025, 2026, and 2027, respectively, with corresponding price-to-earnings (P/E) ratios of 40.94, 36.12, and 32.76 [10][11].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown rapid growth in its main business, although the production of subsidiaries has lowered the overall gross margin. The transformer export value has reached a historical high for four consecutive months [4][9] - The energy structure transformation and the demand for AI computing power are driving the power equipment market into a high growth cycle. The global investment in the power sector is expected to reach $1.5 trillion in 2025, with grid investment surpassing $400 billion for the first time [9] - The company is projected to achieve revenues of 1.65 billion yuan in 2025, with a year-on-year growth rate of 22.46%, and net profits of 48 million yuan, reflecting a growth rate of 11.38% [9] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 1.039 billion yuan, a year-on-year increase of 22.38%, while the net profit attributable to the parent company was 20 million yuan, a decrease of 23.00% [5] - In Q3 2025, the company reported operating revenue of 338 million yuan, a year-on-year increase of 3.14%, but a net loss of 3 million yuan, a decline of 144.87% year-on-year [5] - The gross margin for the first three quarters of 2025 was 12.18%, down 3.97 percentage points year-on-year, and the net margin was 2.01%, down 1.06 percentage points year-on-year [9] Revenue and Profit Forecast - The forecast for total operating revenue from 2025 to 2027 is 1.65 billion yuan, 2.19 billion yuan, and 2.80 billion yuan, with growth rates of 22.46%, 32.89%, and 27.79% respectively [7] - The net profit attributable to the parent company is expected to be 48 million yuan, 65 million yuan, and 89 million yuan for the years 2025 to 2027, with growth rates of 11.38%, 35.21%, and 38.39% respectively [9] - The earnings per share (EPS) for the same period is projected to be 0.25 yuan, 0.34 yuan, and 0.47 yuan [9] Market Performance - The company's stock price has shown relative returns of 11.17% over the past month, 1.63% over the past three months, and 29.62% over the past year compared to the North Securities 50 index [3]

证券研究报告·公司点评报告 2025 年 11 月 5 日 江海证券研究发展部 医药行业研究组 执业证书编号：S1410524050001 | | | 1. 江海证券-公司点评报告-欧康医药 -833230.BJ：2025 年半年报营收增长，利 润承压，关注产能释放和产品结构优化 – 2025.09.02 2. 江海证券-公司深度报告（首次覆盖)- 欧康医药-833230.BJ："槐米+枳实"双 主线产品生态，国内纯植物提取原料药上 市公司 – 2025.05.12 | 总股本(百万股) | | 100.72 | | | --- | --- | --- | --- | | A 股股本(百万股) | | 100.72 | | | B/H 股股本(百万股) | | -/- | | | A 股流通比例(%) | | 46.38 | | | 12 个月最高/最低(元) | | 29.96/13.43 | | | 第一大股东 | | 赵卓君 | | | 第一大股东持股比例(%) | | 40.50 | | | 上证综指/沪深 300 | | 3960.19/4618.70 | | | 数据来源：聚源 | 注：2025 ...

Investment Rating - The investment rating for the company is "Accumulate" (maintained) with a current price of 39.39 yuan [7]. Core Views - The company reported a significant recovery in demand, with third-quarter performance meeting expectations. For the first three quarters of 2025, the company achieved operating revenue of 652 million yuan, a year-on-year increase of 16.62%. The net profit attributable to shareholders was 56 million yuan, up 55.38% year-on-year, and the net profit after deducting non-recurring gains and losses was 55 million yuan, an increase of 77.53% year-on-year. In Q3 2025 alone, the company achieved operating revenue of 243 million yuan, a year-on-year increase of 35.04%, and a net profit attributable to shareholders of 19 million yuan, a staggering increase of 698.40% year-on-year [7][10]. Summary by Sections Revenue Performance - The revenue growth rate in Q3 2025 marked a clear turning point, likely linked to the continued recovery in downstream demand. The operating revenue for Q3 was 243 million yuan, with a year-on-year growth rate of 35.04%, compared to 219 million yuan in Q2 with a growth rate of 17.00%. The recovery in the defense sector and stable development in the aerospace sector contributed to this growth, alongside an expansion in the civil communication high-end equipment business [8]. Profitability - The company's performance in Q3 2025 was impressive, with both gross margin and net margin showing year-on-year improvements. The gross margin for Q3 was 36.09%, an increase of 5.59 percentage points from Q3 2024, while the net margin was 8.87%, up 6.73 percentage points from the previous year. This improvement is attributed to increased production and sales scale, as well as enhanced product profitability [10][11]. Financial Forecast - The company maintains its earnings forecast, expecting operating revenues of 913 million yuan, 1.05 billion yuan, and 1.19 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 19.75%, 14.92%, and 13.00%. The net profit attributable to shareholders is projected to be 123 million yuan, 147 million yuan, and 180 million yuan for the same years, with growth rates of 139.92%, 20.23%, and 22.37% respectively. The earnings per share (EPS) are expected to be 0.65 yuan, 0.79 yuan, and 0.96 yuan for 2025, 2026, and 2027 respectively [12][14].

Investment Rating - The investment rating for the company is upgraded to "Accumulate" [1][5] Core Views - The company has shown a recovery in performance with revenue and profit growth. For the first three quarters of 2025, the company achieved revenue of 411 million yuan, a year-on-year increase of 5.90%, and a net profit attributable to the parent company of 104 million yuan, up 13.45% year-on-year [3][5] - The company focuses on a multi-dimensional product layout and market expansion, primarily leading with APIs while extending into new materials and ensuring a solid reserve of intermediates [5][6] - The company plans to register 1-2 new API varieties annually and is actively pursuing registrations for both old and new products in high-end regulatory markets in Europe and the United States [5][6] Financial Performance Summary - For the first three quarters of 2025, the company reported a gross margin of 47.15%, an increase of 3.61 percentage points year-on-year, and a net margin of 26.31%, up 2.20 percentage points year-on-year [5] - The company’s Q3 revenue was 150 million yuan, representing a 29.45% increase, with a net profit of 35.73 million yuan, up 64.79% year-on-year [5] - The company’s financial forecasts for 2025-2027 indicate expected revenues of 604.89 million yuan, 662.66 million yuan, and 765.83 million yuan, with corresponding net profits of 147.17 million yuan, 170.59 million yuan, and 201.32 million yuan [6][8] Market Position and Strategy - The company is enhancing its competitiveness by extending its industrial chain and exploring emerging markets, aiming for a transition towards proprietary APIs [5][6] - The company has successfully formed commercial orders for new products, indicating a robust pipeline and commitment to innovation [5][6] - The company’s first major shareholder is Jinghua Pharmaceutical Group Co., Ltd., holding a 72.31% stake, which provides a strong backing for its strategic initiatives [1][5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company reported a revenue of 1.296 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 31.10%. The net profit attributable to shareholders was 568 million yuan, up 9.29% year-on-year [4][8] - The sales strategy for functional skincare products includes a focus on proprietary brands and targeted development of raw materials for major clients [8] - The company has successfully registered a new injectable-grade recombinant human collagen material, marking a significant breakthrough in high-end biomedical materials in China [8] Financial Performance Summary - For Q3 2025, the company achieved a revenue of 437 million yuan, with a year-on-year increase of 13.36% but a quarter-on-quarter decrease of 11.22%. The net profit for Q3 was 176 million yuan, down 16.24% year-on-year and 21.17% quarter-on-quarter [4] - The gross margin for the first three quarters of 2025 was 90.80%, a decrease of 1.57 percentage points year-on-year, while the net margin was 43.58%, down 9.02 percentage points year-on-year [8] - The company’s revenue projections for 2025-2027 are 2.041 billion yuan, 2.803 billion yuan, and 3.695 billion yuan, respectively, with year-on-year growth rates of 41.4%, 37.4%, and 31.8% [8][10] Valuation and Investment Recommendations - The current market valuation corresponds to a P/E ratio of 28.9 for 2025, 20.8 for 2026, and 15.5 for 2027 [8][10] - The company is positioned as a leader in the recombinant collagen market and is continuously expanding into new application areas [8]

Investment Rating - The investment rating for the company is upgraded to "Accumulate" [5] Core Insights - The company reported steady growth in its performance, with a revenue of 7.098 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 1.89%. The net profit attributable to shareholders was 1.026 billion yuan, up 2.65% year-on-year [5][8] - The company experienced a decline in revenue and net profit in Q3 2025, with revenue of 1.736 billion yuan, down 11.63% year-on-year and 42.18% quarter-on-quarter. The net profit for the same period was 227 million yuan, down 23.64% year-on-year and 44.35% quarter-on-quarter [5][8] - The company maintained a high gross margin of 73.69% for the first three quarters of 2025, an increase of 3.62 percentage points year-on-year, and a net profit margin of 14.86%, up 0.18 percentage points year-on-year [8] Financial Performance Summary - Revenue projections for 2025-2027 are 12.002 billion yuan, 13.427 billion yuan, and 15.081 billion yuan, with year-on-year growth rates of 11.36%, 11.87%, and 12.32% respectively [7][8] - Net profit projections for the same period are 1.643 billion yuan, 1.783 billion yuan, and 1.986 billion yuan, with growth rates of 5.87%, 8.53%, and 11.38% respectively [7][8] - The company's return on equity (ROE) is projected to decline from 24.84% in 2025 to 20.78% in 2027 [11][12] Market Position and Competitive Landscape - The company has maintained strong rankings across multiple platforms during the "Double 11" sales event, with its main brand ranking first in Tmall's beauty category and other brands also performing well [8] - The company is focusing on a strategy of "new product expansion and solidifying core products," with significant growth in its high-end product lines [8] - The competitive landscape in the cosmetics industry is intensifying, with the company's color cosmetics brand becoming a key growth driver [8]

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [6][12]. Core Views - The company reported a revenue of 188 million yuan for the first three quarters of 2025, representing a year-on-year growth of 15.57%. The net profit attributable to the parent company was 63 million yuan, up 25.28% year-on-year [6]. - The third quarter of 2025 saw a revenue of 89 million yuan, with a year-on-year increase of 9.26%, while the net profit attributable to the parent company reached 31 million yuan, growing by 26.37% year-on-year [6][9]. - The report indicates that the company's performance is in line with expectations, with improvements in both gross margin and net margin compared to the same period last year [8][9]. Summary by Sections Revenue Performance - The revenue growth rate in the third quarter continued to decline, potentially due to seasonal factors. The revenue for Q3 2025 was 89 million yuan, down from 56 million yuan in Q2 2025, which had a growth rate of 13.57% [7]. - The report anticipates a potential turnaround in performance for the fourth quarter, as revenue recognition in the aerospace industry is primarily concentrated in the second half of the year [7]. Profitability - The overall profitability is in line with expectations, with the gross margin for Q3 2025 at 57.68%, an increase of 6.90 percentage points year-on-year, and the net margin at 34.43%, up 4.67 percentage points year-on-year [9]. Financial Forecast - The company is projected to achieve revenues of 377 million yuan, 476 million yuan, and 589 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 30.63%, 26.31%, and 23.73% [10][12]. - The net profit attributable to the parent company is expected to be 110 million yuan, 142 million yuan, and 174 million yuan for the same years, with growth rates of 28.95%, 29.57%, and 22.25% respectively [10][12].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company has shown stable growth in revenue and profit, with a 15.69% year-on-year increase in revenue and a 25.93% increase in net profit for the first three quarters of 2025 [5][7] - The company is expected to maintain a growth trend due to the release of new production capacity and expansion into international markets [7][8] Summary by Sections Financial Performance - For the first three quarters of 2025, the company achieved revenue of 293 million yuan, a year-on-year increase of 15.69%, and a net profit of 48.06 million yuan, up 25.93% [5][7] - The gross margin for the first three quarters was 31.87%, an increase of 2.06 percentage points year-on-year, while the net margin was 16.43%, up 1.34 percentage points [7] - The company’s revenue from exports accounted for approximately 56.88%, indicating a recovery in foreign market demand [7] Growth Drivers - The company is currently undergoing trial production and product validation for new factories, which will help alleviate existing capacity constraints [7] - Expansion into international markets through subsidiaries in Singapore, the Netherlands, and the United States is expected to enhance local market service and increase international market share [7] - The company is also exploring new product categories beyond amino acids, such as amino acid derivatives and functional peptides, which could provide additional revenue streams [7] Valuation and Forecast - The company’s revenue is projected to grow from 400.06 million yuan in 2025 to 556.52 million yuan in 2027, with year-on-year growth rates of 18.02%, 18.44%, and 17.45% respectively [9] - The net profit forecast for the same period is 59.71 million yuan in 2025, increasing to 86.98 million yuan by 2027, with growth rates of 39.35%, 14.72%, and 26.98% [9] - The current market valuation corresponds to a price-to-earnings ratio (P/E) of 36.69 for 2025, decreasing to 25.19 by 2027 [9]

证券研究报告·公司点评报告 2025 年 11 月 3 日 江海证券研究发展部 医药行业研究组 执业证书编号：S1410524050001 | | | | 市场数据 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 总股本(百万股) | | 98.46 | | | | | | | | A 股股本(百万股) | | 98.46 | | | | | | | | B/H 股股本(百万股) | | | | | | -/- | | | | A 股流通比例(%) | | 56.16 | | | | | | | | 12 个月最高/最低(元) | | 40.48/10.53 | | | | | | | | 第一大股东 | | | | | | | | 王敏 | | 第一大股东持股比例(%) | | 25.81 | | | | | | | | 上证综指/沪深 300 | | | | | | | 3954.79/4640.67 | | | 数据来源：聚源 注：2025 | 月 | 日数据 | 年 | 10 | 31 | | | ...